Author Archives: Marisa Wexler MS

Meaningful Cognitive Gains in Pediatric MS Captured Using Pencil-Paper Test

A computer-based training program that exercises distinct components of attention and working memory can improve cognition in young people with pediatric-onset multiple sclerosis (POMS), a new study indicates. Findings also support a common pencil-and-paper measure of cognition, called the Symbol Digit Modalities Test (SDMT), in detecting clinically meaningful changes…

DMTs Underutilized in Younger Patients, Study Indicates

Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with disease-modifying treatments (DMTs), even though younger individuals are expected to get the most benefit from DMTs, according to a new study. “DMTs for MS are more frequently used at…

Immersive Virtual Reality May Improve Treadmill Gait Training

Immersive virtual reality may make treadmill exercise more engaging and effective for people with multiple sclerosis (MS) or other conditions that can make walking difficult, according to new research. The findings were published in the Journal of NeuroEngineering and Rehabilitation, in the study “Immersive virtual reality…

Male Immune Cells Drive More Severe MS, Study Suggests

Due to differences in sex chromosomes, certain immune cells cause more severe disease in males than females, according to a new study in a mouse model of multiple sclerosis (MS). The findings could help to explain why biological males with MS tend to have more severe disease. The study,…

Safety of Oral DMTs for RRMS in Real-world Use Seen to Match Trial Findings

People with relapsing-remitting multiple sclerosis (RRMS) using approved oral disease-modifying therapies generally tolerate the treatments well, with real-world adverse event profiles similar to those seen in clinical trials, an analysis of U.S. data indicates. Results also suggest high adherence to these therapies — meaning patients are usually taking the therapies…

#AANAM – Exploring Mavenclad’s Effects on Immune Cells

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

#AANAM – Research Focuses on Measuring Therapeutic Lag

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read the latest stories from the conference. A novel method to calculate how long it takes therapies for multiple sclerosis (MS) to become fully effective…

#AANAM – Early Ocrevus Treatment Helps to Protect Nervous System

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage…

#AANAM – Abnormally Warm Weather Tied to More ER Visits

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care,…

Under-the-skin Injection of Tysabri Approved in Europe

The European Commission (EC) has approved a new method to administer Tysabri (natalizumab) as a treatment for people with relapsing-remitting multiple sclerosis (RRMS). This new delivery route involves a subcutaneous injection in which Tysabri is injected under the skin. Compared with the previously approved intravenous (into the bloodstream) formulation,…

N-acetyl Cysteine Safe, But Failed to Lessen MS Fatigue

Treatment with the antioxidant N‐acetyl cysteine is well-tolerated, but failed to outperform a placebo at easing fatigue in people with progressive multiple sclerosis (MS), a small clinical trial found. More studies now are needed to determine if oxidative stress contributes to fatigue or clinical progression in MS patients, and…

Certain Factors Worsen Outcomes in MS Patients With COVID-19

People with multiple sclerosis (MS) who have more extensive mobility issues are more likely to have worse outcomes from COVID-19, a new study indicates. The study findings also indicate that COVID-19-associated outcomes are worse among MS patients who are Black, older, have heart-related diseases, and who were treated with…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Survey Icon

Video